Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Information source: Boehringer Ingelheim Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cerebrovascular Accident
Intervention: Aggrenox® modified release capsules (Drug); Aggrenox® modified release capsules matching placebo (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Boehringer Ingelheim Pharmaceuticals Official(s) and/or principal investigator(s):
Boehringer Ingelheim Study Coordinator, Study Chair, Affiliation: B.I. Taiwan Ltd.
Summary
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b. i.d,
compared to reduced dose during the first two weeks of treatment in a double-blind,
randomized controlled parallel group comparison trial among Taiwanese patients with previous
TIA's or ischemic stroke. To monitor frequency and intensity of headaches and other safety
parameters among Taiwanese patients with previous TIA's or ischemic stroke given Aggrenox
using a titration scheme or not
Clinical Details
Official title: Tolerability of a Four Week Treatment With Asasantin Extended Released 200/25 mg Capsules b.i.d, Compared to Reduced Dose During the First Two Week of Treatment in a Double-Blind, Randomized Placebo Controlled Parallel Group Comparison Trial Among Taiwanese Patients With Previous TIA&Apos;s or Ischemic s
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study
Primary outcome: Cumulated headache (intensity x frequency) over the first three days of treatment period
Secondary outcome: Proportion of (1) subjects drop out due to drug related AE and (2) experiencing grade 3 or 4 drug related headache during day 5-14, day 15-21 (reduced dose), day 5-11 (regular dose), day 7, day 28; as well as (3) Number of acetaminophen tablets used.
Detailed description:
The major objective of the study is to evaluate the tolerance of headache and safety in
Taiwan Taiwanese patients who are receiving two different dosing regimens of Aggrenox and
Aggrenox placebo. The first group will start with placebo on days 1-4, daily dose on days
5-14, and following by b. i.d treatment on 15-28 days. This group will also receive a matching
placebo in the morning and one Aggrenox capsule in the evening before on days 5-14. It
enables to reduce the perception of dipyridamole-associated headache. The second group will
receive the placebo twice daily on days 1-4, and medication twice daily for the remaining
course. The third group will receive the placebo twice daily for the whole course.
Study Hypothesis:
NULL AND ALTERNATIVE HYPOTHESES
From a subject diary, asking for the most frequent side effects observed in the ESPS2 trial,
the cumulative headache (intensity x frequency) per day based on the first three days of
treatment period defines the primary endpoint.
I: H0: Median cumulative headache is equal for all treatment groups vs. HA: Median cumulative
headache is not equal for all treatment groups
II: H0: Median cumulative headache of low dose regimen?Median cumulative headache of regular
dose vs. HA: Median cumulative headache of low dose regimen < Median cumulative headache of
regular dose
Comparison(s):
Compare Aggrenox full dose, reduced dose and placebo
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. 20 years old or above.
2. History of TIA or completed ischemic stroke
3. Signed informed consent.
4. Patient with score < 2 on modified Rankin's Classification of Neurological Status.
Exclusion Criteria:
1. Patients with known or suspected prior intracranial haemorrhage or history of brain
injury or brain tumor.
2. Disorders related to syncope, dropattacks, congenital vascular malformation, aneurysm,
angioma, or epilepsy, psychiatric disorders.
3. Peptic ulcer or gastrointestinal bleeding within 6 months.
4. History of hypersensitivity or intolerance to study drugs or aspirin.
5. Experienced habitual headache (any form) within the past 3 months.
6. History of dysphasia, dysphagia, dementia, or unconsciousness.
7. Patients currently taking other medications known to cause headaches (e. g. nitrates).
8. Patients with deteriorating angina, subvalvular aortic stenosis or hemodynamic
liability (e. g. in conjunction with a recent myocardial infarction).
9. Uncontrolled hypertension (SBP > 220 mmHg, DBP> 120 mmHg) or life-threatening
disease.
10. Any significant disorders, such as chronic renal failure(serum creatinine > 2. 0
mg/dl), neoplasia.
11. SGPT, SGOT value greater than 2 times of the upper normal limit.
12. Insulin dependent diabetes mellitus or poorly controlled non-insulin dependent
diabetes mellitus (AC sugar > 300 mg/dl).
13. Use of other anticoagulants, such as anti-coagulated agents or NSAIDsS.
14. History of alcohol and/or drug abuse.
15. Having participated in other investigational drug study within 3 months prior to study
entry.
16. Pregnant or lactating women or women of childbearing potential whom are not practicing
reliable birth control.
17. The patients who take methylxanthine-containing drinks or foods (coffee, black tea,
cola, energy drink, etc.) more than 4 cups of coffee or it's equivalents.
Locations and Contacts
Chang Gung Memorial Hospital, Taipei 105, Taiwan
Additional Information
Starting date: September 2002
Ending date: April 2003
Last updated: April 8, 2008
|
